Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M717Revenue $M13.6Net Margin (%)-332.1Z-Score2.0
Enterprise Value $M674EPS $-0.7Operating Margin %-336.4F-Score2
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-332.1Higher ROA y-yN
Price/Book9.410-y EBITDA Growth Rate %-6.8Quick Ratio1.5Cash flow > EarningsY
Price/Sales47.25-y EBITDA Growth Rate %4.1Current Ratio1.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-44.5Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-93.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M72.3ROI % (ttm)-126.5Gross Margin Increase y-yN

Gurus Latest Trades with BCRX

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BCRXGeorge Soros 2014-06-30 Sold Out -0.01%$7.37 - $12.52
($9.68)
$ 10.356%Sold Out0
BCRXGeorge Soros 2014-03-31 Buy 0.01%$7.6 - $12.83
($10.56)
$ 10.35-2%New holding59,700
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BCRX is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


BCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Babu Yarlagadda SSenior VP - Drug Discovery 2015-03-19Sell12,105$10.161.87 view
Babu Yarlagadda SSenior VP - Drug Discovery 2015-03-05Sell37,400$10.59-2.27 view
Babu Yarlagadda SSenior VP - Drug Discovery 2015-03-04Sell10,495$10.5-1.43 view
Hutson Nancy JDirector 2015-02-20Buy10,000$10.270.78 view
Sheridan William PSenior VP - CMO 2014-12-30Sell128,399$12.36-16.26 view
STAAB THOMAS R IISenior Vice President and CFO 2014-12-29Sell9,500$12.56-17.6 view
STAAB THOMAS R IISenior Vice President and CFO 2014-08-27Sell10,000$13.58-23.78 view
STAAB THOMAS R IISenior Vice President and CFO 2014-07-01Sell3,125$13-20.38 view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-23Sell3,125$12.49-17.13 view
STAAB THOMAS R IISenior Vice President and CFO 2014-06-17Sell3,125$12-13.75 view

Press Releases about BCRX :

    Quarterly/Annual Reports about BCRX:

    News about BCRX:

    Articles On GuruFocus.com
    comment on BCRX Mar 02 2013 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
    BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
    BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 


    More From Other Websites
    Nasdaq stocks posting largest percentage increases Apr 24 2015
    BioCryst to Announce First Quarter 2015 Financial Results May 8 Apr 23 2015
    BioCryst to Announce First Quarter 2015 Financial Results May 8 Apr 23 2015
    Coverage initiated on BioCryst Pharm by FBR Capital Apr 21 2015
    BioCryst Upgrade Almost Looks Misunderstood Apr 20 2015
    BofA: We're Upgrading Biocryst Pharmaceuticals Apr 20 2015
    5 Big Biotechs Not Keeping Up at All With Hot Biotech Sector in 2015 Apr 18 2015
    2 Pairs Trades To Avoid A Market Correction Apr 16 2015
    BioCryst to Present at the Needham Healthcare Conference Apr 07 2015
    BioCryst to Present at the Needham Healthcare Conference Apr 07 2015
    Dyax Soars As Rare-Disease Drug Wows Wall Street Apr 01 2015
    BioCryst Pharmaceuticals (BCRX) Jumps: Stock Adds 5.4% - Tale of the Tape Apr 01 2015
    Ebola Finances Coming Back in the News Mar 31 2015
    Durham's BioCryst gets $35M federal contract for Ebola treatment Mar 31 2015
    BioCryst (BCRX) Stock Gains Today on Ebola Treatment Contract With U.S. Government Mar 31 2015
    BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Mar 31 2015
    BioCryst wins US contract to continue Ebola drug development Mar 31 2015
    BioCryst Pharma wins federal contract to continue making Ebola drug Mar 31 2015
    BioCryst Awarded BCX4430 Advanced Development Contract Mar 31 2015
    BioCryst Awarded BCX4430 Advanced Development Contract Mar 31 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK